GOODLIFE PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
GOODLIFE PHARMA
Largest movements
- Stocks and contracts -€2.7m
down €2.7m (-91.4%), from €3.0m to €253,177
- Receivables within one year +€1.6m
up €1.6m (+86.4%), from €1.8m to €3.4m
of which Trade receivables: +€1.6m
- Cash +€176,410
up €176,410 (+459%), from €38,419 to €214,829
mainly Stocks and contracts (+€2.7m) and Debts after one year (+€1.0m)
- Deferred charges and accrued income +€120,707
up €120,707 (+322%), from €37,480 to €158,187
- Trade debts -€1.8m
down €1.8m (-85.5%), from €2.2m to €312,749
- Debts after one year +€1.0m
up €1.0m (+89.9%), from €1.1m to €2.2m
- Accrued charges and deferred income -€211,061
down €211,061 (-83.3%), from €253,489 to €42,428
- Profit (loss) carried forward +€119,670
up €119,670 (+33.1%), from €361,052 to €480,723
- Other debts +€54,942
up €54,942 (+50.0%), from €109,865 to €164,807
- Other operating charges +€453,522
up €453,522 (+4,005%), from €11,324 to €464,846
- Gross operating margin +€236,139
up €236,139 (+25.7%), from €917,755 to €1.2m
- Taxes -€39,095
down €39,095 (-43.5%), from €89,795 to €50,700
- Staff costs -€25,534
down €25,534 (-5.2%), from €492,096 to €466,563
- Depreciation +€14,245
up €14,245 (+160%), from €8,913 to €23,158
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €5,121,062 | €4,304,421 | -€816,640 | -15.9% |
| Fixed assets | 21/28 | €103,454 | €105,046 | +€1,592 | +1.5% |
| Intangible fixed assets | 21 | - | €23,852 | +€23,852 | |
| Tangible fixed assets | 22/27 | €90,442 | €68,182 | -€22,259 | -24.6% |
| Plant, machinery and equipment | 23 | €1,324 | €1,160 | -€164 | -12.4% |
| Furniture and vehicles | 24 | €12,989 | €7,571 | -€5,418 | -41.7% |
| Other tangible fixed assets | 26 | €76,129 | €59,452 | -€16,677 | -21.9% |
| Financial fixed assets | 28 | €13,013 | €13,013 | = | 0.0% |
| Current assets | 29/58 | €5,017,607 | €4,199,375 | -€818,233 | -16.3% |
| Stocks and contracts in progress | 3 | €2,953,682 | €253,177 | -€2.7m | -91.4% |
| Stocks | 30/36 | €2,953,682 | €253,177 | -€2.7m | -91.4% |
| Amounts receivable within one year | 40/41 | €1,834,037 | €3,419,192 | +€1.6m | +86.4% |
| Trade receivables | 40 | €1,744,598 | €3,299,333 | +€1.6m | +89.1% |
| Other amounts receivable | 41 | €89,439 | €119,859 | +€30,419 | +34.0% |
| Current investments | 50/53 | €153,990 | €153,990 | = | 0.0% |
| Cash at bank and in hand | 54/58 | €38,419 | €214,829 | +€176,410 | +459% |
| Deferred charges and accrued income | 490/1 | €37,480 | €158,187 | +€120,707 | +322% |
| Total equity and liabilities | 10/49 | €5,121,062 | €4,304,421 | -€816,640 | -15.9% |
| Equity | 10/15 | €649,802 | €769,473 | +€119,670 | +18.4% |
| Contributions | 10/11 | €262,500 | €262,500 | = | 0.0% |
| Capital | 10 | €262,500 | €262,500 | = | 0.0% |
| Issued capital | 100 | €262,500 | €262,500 | = | 0.0% |
| Reserves | 13 | €26,250 | €26,250 | = | 0.0% |
| Non-distributable reserves | 130/1 | €26,250 | €26,250 | = | 0.0% |
| Legal reserve | 130 | €26,250 | €26,250 | = | 0.0% |
| Profit (loss) carried forward | 14 | €361,052 | €480,723 | +€119,670 | +33.1% |
| Amounts payable | 17/49 | €4,471,259 | €3,534,949 | -€936,311 | -20.9% |
| Amounts payable after more than one year | 17 | €1,140,000 | €2,165,000 | +€1.0m | +89.9% |
| Financial debts | 170/4 | €1,140,000 | €2,165,000 | +€1.0m | +89.9% |
| Amounts payable within one year | 42/48 | €3,077,770 | €1,327,520 | -€1.8m | -56.9% |
| Financial debts | 43 | €750,000 | €750,000 | = | 0.0% |
| Credit institutions | 430/8 | €750,000 | €750,000 | = | 0.0% |
| Trade debts | 44 | €2,153,658 | €312,749 | -€1.8m | -85.5% |
| Suppliers | 440/4 | €2,153,658 | €312,749 | -€1.8m | -85.5% |
| Taxes, remuneration and social security | 45 | €64,247 | €99,965 | +€35,718 | +55.6% |
| Taxes | 450/3 | €155 | €50,793 | +€50,638 | +32,742% |
| Remuneration and social security | 454/9 | €64,092 | €49,172 | -€14,920 | -23.3% |
| Other amounts payable | 47/48 | €109,865 | €164,807 | +€54,942 | +50.0% |
| Accrued charges and deferred income | 492/3 | €253,489 | €42,428 | -€211,061 | -83.3% |
| Remuneration, social security and pensions | 62 | €492,096 | €466,563 | -€25,534 | -5.2% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €8,913 | €23,158 | +€14,245 | +160% |
| Other operating charges | 640/8 | €11,324 | €464,846 | +€453,522 | +4,005% |
| Gross operating margin | 9900 | €917,755 | €1,153,894 | +€236,139 | +25.7% |
| Operating profit (loss) | 9901 | €405,422 | €199,327 | -€206,095 | -50.8% |
| Financial income | 75/76B | €7,701 | €21,510 | +€13,809 | +179% |
| Recurring financial income | 75 | €7,701 | €21,510 | +€13,809 | +179% |
| Financial charges | 65/66B | €63,525 | €50,467 | -€13,058 | -20.6% |
| Recurring financial charges | 65 | €63,525 | €50,467 | -€13,058 | -20.6% |
| Profit (loss) for the period before taxes | 9903 | €349,598 | €170,370 | -€179,228 | -51.3% |
| Income taxes | 67/77 | €89,795 | €50,700 | -€39,095 | -43.5% |
| Profit (loss) for the period | 9904 | €259,803 | €119,670 | -€140,133 | -53.9% |
| Profit (loss) for the period to be appropriated | 9905 | €259,803 | €119,670 | -€140,133 | -53.9% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 19 October 2026 via checked.be.